Clinical trial
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure…
NCT04625725 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT04625725 |
|---|---|
| Title | Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. |
| Official title | A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19. |
| Acronym | PROVENT |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Iqvia Pty Ltd Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | COVID-19 |
| Intervention type | Drug |
| Interventions | AZD7442, Placebo |
| Enrollment | 5,197 |
| Start date | Nov 21, 2020 |
| Primary completion | Aug 16, 2022 |
| Completion | Dec 8, 2023 |
| First posted | Nov 12, 2020 |
| Last update posted | Dec 31, 2024 |
| Countries | Belgium, France, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: